Actively Recruiting
Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes
Led by University Hospital, Limoges · Updated on 2024-12-13
60
Participants Needed
1
Research Sites
87 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this pilot study is that exosomes constitute a more interesting support for analyzes allowing a broader screening of molecular alterations to be carried out with more reliable, more sensitive and more efficient results than the reference Foundation One Liquid CDx test.
CONDITIONS
Official Title
Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older with glioblastoma
- Patients for whom a Foundation Medicine Inc. (FMI) test is indicated and who have progressed after first-line chemotherapy and radiotherapy following the STUPP protocol
- Patients affiliated with French social security
You will not qualify if you...
- Patients enrolled in another research protocol using an experimental drug
- Any medical or psychiatric condition that could prevent adherence to the study or completion per protocol, as judged by the investigator
- Patients under legal protection, guardianship, or curatorship
- Patients with active malignancy or a previous malignancy within the past 5 years, except for resected basal cell carcinoma and resected carcinoma in-situ of the cervix
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Limoges
Limoges, France, 87042
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here